<p>Drug firm Shilpa Medicare on Monday said its arm has entered into a definitive agreement with Dr Reddy's Laboratories for manufacturing of Russian COVID-19 vaccine Sputnik V.</p>.<p>"The company, via its wholly owned subsidiary Shilpa Biologicals Pvt Ltd (SBPL), has entered into a three year definitive agreement with Dr Reddy's Laboratories for production-supply of the Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka," Shilpa Medicare said in a regulatory filing.</p>.<p>The targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses (50 million of component 1 and 50 million of component 2), from the date of start of commercial production, the company added.</p>.<p>Shilpa Medicare said Dr Reddy's will facilitate the transfer of the sputnik technology to SBPL.</p>.<p>Under the agreement, SBPL will be responsible for manufacture of the vaccine, while Dr Reddy's is responsible for distribution/marketing of the vaccine in its marketing territories.</p>.<p>Shilpa Medicare said the companies are also exploring the option to manufacture Sputnik Light, a single dose version of the vaccine in the near future.</p>.<p>Reddy's Laboratories on Friday soft-launched imported COVID-19 vaccine Sputnik V, with Deepak Sapra, a senior executive of the drug-maker, taking the first shot.</p>.<p>The vaccine is priced at Rs 948, with five per cent GST per dose (retail price of Rs 995.40).</p>.<p>The first consignment of imported doses of the Sputnik V vaccine from Russian Direct Investment Fund (RDIF) landed in India on May 1, and received regulatory clearance from the Central Drugs Laboratory.</p>
<p>Drug firm Shilpa Medicare on Monday said its arm has entered into a definitive agreement with Dr Reddy's Laboratories for manufacturing of Russian COVID-19 vaccine Sputnik V.</p>.<p>"The company, via its wholly owned subsidiary Shilpa Biologicals Pvt Ltd (SBPL), has entered into a three year definitive agreement with Dr Reddy's Laboratories for production-supply of the Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka," Shilpa Medicare said in a regulatory filing.</p>.<p>The targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses (50 million of component 1 and 50 million of component 2), from the date of start of commercial production, the company added.</p>.<p>Shilpa Medicare said Dr Reddy's will facilitate the transfer of the sputnik technology to SBPL.</p>.<p>Under the agreement, SBPL will be responsible for manufacture of the vaccine, while Dr Reddy's is responsible for distribution/marketing of the vaccine in its marketing territories.</p>.<p>Shilpa Medicare said the companies are also exploring the option to manufacture Sputnik Light, a single dose version of the vaccine in the near future.</p>.<p>Reddy's Laboratories on Friday soft-launched imported COVID-19 vaccine Sputnik V, with Deepak Sapra, a senior executive of the drug-maker, taking the first shot.</p>.<p>The vaccine is priced at Rs 948, with five per cent GST per dose (retail price of Rs 995.40).</p>.<p>The first consignment of imported doses of the Sputnik V vaccine from Russian Direct Investment Fund (RDIF) landed in India on May 1, and received regulatory clearance from the Central Drugs Laboratory.</p>